BRITISH pharmaceutical giant GSK is buying COVID and influenza vaccines from CureVac, reported Reuters. It will pay CureVac 400m (A$642m) upfront and up to 1.05b (A$1.69b) contingent on achievements.
CureVac shares surged 24% higher on the news. As a result of the acquisition, CureVac which will lay off 30% of its staff to focus on mRNA projects in oncology.
This is in addition to the 1,000 jobs it slashed in Apr, as a result of its failure to develop an mRNA-based COVID vaccine during the pandemic.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jul 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jul 24
